November 3, 2023 in Kineta Press Release

Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

  Lead Anti-CD27 Monoclonal Antibody Showed High Binding Affinity and Specificity Drives Strong T Cell Activation and Proliferation as well as NK Cell Activation Demonstrated In Vivo Antitumo ...

Read More
November 3, 2023 in KVA1213 Publications

VISTA-101: A phase 1/2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA alone and in combination with pembrolizumab in advanced solid tumors

Thierry Guillaudeux, Phd, Chief Scientific Officer Society for Immunotherapy of Cancer (SITC) 2023 | November 3, 2023

Read More